Thus all of the DNA synthetic effects of B 12 deficiency, including the megaloblastic anemia of pernicious anemia, resolve if sufficient dietary folate is present
Within this population: 8,533 individuals were included in the semaglutide versus other glucose-lowering drug comparison (2,397 vs 6,136) 7,455 individuals were included in the semaglutide versus SGLT2 inhibitor comparison (1,650 vs 3,725) Key findings reduced risk of seizures After statistical adjustment, initiation of semaglutide was associated with a lower risk of epilepsy or seizures compared with both comparator groups: Compared with other glucose-lowering drugs: Hazard ratio: 0.46 95% confidence interval: 0.250.83 P = .010 Compared with SGLT2 inhibitors: Hazard ratio: 0.44 95% confidence interval: 0.220.86 P = .017 These findings suggest a meaningful reduction in relative risk among those initiating semaglutide
Results: Between 2012 and 2021, the proportion of women aged 35 years or more at delivery increased from 19.1% to 24.3%
This article explains why deficiency occurs, how B12 absorption is affected, when intramuscular injections are indicated, and what long-term monitoring after gastric banding should involve